141 related articles for article (PubMed ID: 18537665)
1. Nonsteroidal anti-inflammatory drugs in experimental parkinsonian models and Parkinson's disease.
Asanuma M; Miyazaki I
Curr Pharm Des; 2008; 14(14):1428-34. PubMed ID: 18537665
[TBL] [Abstract][Full Text] [Related]
2. Nonsteroidal anti-inflammatory drugs in Parkinson's disease: possible involvement of quinone formation.
Asanuma M; Miyazaki I
Expert Rev Neurother; 2006 Sep; 6(9):1313-25. PubMed ID: 17009919
[TBL] [Abstract][Full Text] [Related]
3. Neuroprotective effects of nonsteroidal anti-inflammatory drugs on neurodegenerative diseases.
Asanuma M; Miyazaki I; Ogawa N
Curr Pharm Des; 2004; 10(6):695-700. PubMed ID: 14965332
[TBL] [Abstract][Full Text] [Related]
4. [New aspects of neuroprotective effects of nonsteroidal anti-inflammatory drugs].
Asanuma M; Miyazaki I; Tsuji T; Ogawa N
Nihon Shinkei Seishin Yakurigaku Zasshi; 2003 Jun; 23(3):111-9. PubMed ID: 12884751
[TBL] [Abstract][Full Text] [Related]
5. Non-steroidal anti-inflammatory drugs in Parkinson's disease.
Esposito E; Di Matteo V; Benigno A; Pierucci M; Crescimanno G; Di Giovanni G
Exp Neurol; 2007 Jun; 205(2):295-312. PubMed ID: 17433296
[TBL] [Abstract][Full Text] [Related]
6. Reduction of nuclear peroxisome proliferator-activated receptor gamma expression in methamphetamine-induced neurotoxicity and neuroprotective effects of ibuprofen.
Tsuji T; Asanuma M; Miyazaki I; Miyoshi K; Ogawa N
Neurochem Res; 2009 Apr; 34(4):764-74. PubMed ID: 18946735
[TBL] [Abstract][Full Text] [Related]
7. Common anti-inflammatory drugs are potentially therapeutic for Parkinson's disease?
Asanuma M; Miyazaki I
Exp Neurol; 2007 Aug; 206(2):172-8. PubMed ID: 17599833
[No Abstract] [Full Text] [Related]
8. Dynamic changes in pro- and anti-inflammatory cytokines in microglia after PPAR-γ agonist neuroprotective treatment in the MPTPp mouse model of progressive Parkinson's disease.
Pisanu A; Lecca D; Mulas G; Wardas J; Simbula G; Spiga S; Carta AR
Neurobiol Dis; 2014 Nov; 71():280-91. PubMed ID: 25134730
[TBL] [Abstract][Full Text] [Related]
9. Meloxicam ameliorates motor dysfunction and dopaminergic neurodegeneration by maintaining Akt-signaling in a mouse Parkinson's disease model.
Tasaki Y; Yamamoto J; Omura T; Sakaguchi T; Kimura N; Ohtaki K; Ono T; Suno M; Asari M; Ohkubo T; Noda T; Awaya T; Shimizu K; Matsubara K
Neurosci Lett; 2012 Jul; 521(1):15-9. PubMed ID: 22617635
[TBL] [Abstract][Full Text] [Related]
10. Possible role of propofol's cyclooxygenase-inhibiting property in alleviating dopaminergic neuronal loss in the substantia nigra in an MPTP-induced murine model of Parkinson's disease.
Kubo K; Inada T; Shingu K
Brain Res; 2011 Apr; 1387():125-33. PubMed ID: 21376018
[TBL] [Abstract][Full Text] [Related]
11. Neuroprotective effect of kaempferol against a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease.
Li S; Pu XP
Biol Pharm Bull; 2011; 34(8):1291-6. PubMed ID: 21804220
[TBL] [Abstract][Full Text] [Related]
12. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease.
Du Y; Ma Z; Lin S; Dodel RC; Gao F; Bales KR; Triarhou LC; Chernet E; Perry KW; Nelson DL; Luecke S; Phebus LA; Bymaster FP; Paul SM
Proc Natl Acad Sci U S A; 2001 Dec; 98(25):14669-74. PubMed ID: 11724929
[TBL] [Abstract][Full Text] [Related]
13. Neuroprotective effects of Astilbin on MPTP-induced Parkinson's disease mice: Glial reaction, α-synuclein expression and oxidative stress.
Zhu YL; Sun MF; Jia XB; Cheng K; Xu YD; Zhou ZL; Zhang PH; Qiao CM; Cui C; Chen X; Yang XS; Shen YQ
Int Immunopharmacol; 2019 Jan; 66():19-27. PubMed ID: 30419450
[TBL] [Abstract][Full Text] [Related]
14. Dual acting anti-inflammatory drugs: a reappraisal.
Bertolini A; Ottani A; Sandrini M
Pharmacol Res; 2001 Dec; 44(6):437-50. PubMed ID: 11735348
[TBL] [Abstract][Full Text] [Related]
15. Nonsteroidal anti-inflammatory drugs in clinical and experimental epilepsy.
Radu BM; Epureanu FB; Radu M; Fabene PF; Bertini G
Epilepsy Res; 2017 Mar; 131():15-27. PubMed ID: 28212985
[TBL] [Abstract][Full Text] [Related]
16. A story of the potential effect of non-steroidal anti-inflammatory drugs (NSAIDs) in Parkinson's disease: beneficial or detrimental effects.
Alrouji M; Al-Kuraishy HM; Al-Gareeb AI; Saad HM; Batiha GE
Inflammopharmacology; 2023 Apr; 31(2):673-688. PubMed ID: 36961665
[TBL] [Abstract][Full Text] [Related]
17. Differential susceptibility to the PPAR-γ agonist pioglitazone in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 6-hydroxydopamine rodent models of Parkinson's disease.
Laloux C; Petrault M; Lecointe C; Devos D; Bordet R
Pharmacol Res; 2012 May; 65(5):514-22. PubMed ID: 22391246
[TBL] [Abstract][Full Text] [Related]
18. Anti-inflammatory and anti-apoptotic effects of (RS)-glucoraphanin bioactivated with myrosinase in murine sub-acute and acute MPTP-induced Parkinson's disease.
Galuppo M; Iori R; De Nicola GR; Bramanti P; Mazzon E
Bioorg Med Chem; 2013 Sep; 21(17):5532-47. PubMed ID: 23810671
[TBL] [Abstract][Full Text] [Related]
19. Neuroprotective strategies in Parkinson's disease : an update on progress.
Mandel S; Grünblatt E; Riederer P; Gerlach M; Levites Y; Youdim MB
CNS Drugs; 2003; 17(10):729-62. PubMed ID: 12873156
[TBL] [Abstract][Full Text] [Related]
20. Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson's disease: possible involvement of different binding sites at the PPARγ receptor.
García C; Gómez-Cañas M; Burgaz S; Palomares B; Gómez-Gálvez Y; Palomo-Garo C; Campo S; Ferrer-Hernández J; Pavicic C; Navarrete C; Luz Bellido M; García-Arencibia M; Ruth Pazos M; Muñoz E; Fernández-Ruiz J
J Neuroinflammation; 2018 Jan; 15(1):19. PubMed ID: 29338785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
